Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Menstrual cycle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    409 result(s) found for: Menstrual cycle. Displaying page 7 of 21.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2017-005005-12 Sponsor Protocol Number: D2.D12.Bemfola Start Date*: 2018-05-28
    Sponsor Name:UZ Brussel
    Full Title: Initiation of ovarian stimulation with recombinant-human FSH (Bemfola®) in the late follicular phase, a randomised controlled study.
    Medical condition: Subfertility Oocyte donation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10042392 Subfertility (female) LLT
    20.0 10042613 - Surgical and medical procedures 10053370 Oocyte donation PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003049-37 Sponsor Protocol Number: CS-10459 Start Date*: 2022-11-23
    Sponsor Name:UZ Brussel
    Full Title: Luteal phase ovarian stimulation with Follitropin delta and dydrogesterone: a randomized cross over pilot trial
    Medical condition: Volutary women who wish to donate their oocytes
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001950-16 Sponsor Protocol Number: ISI-2015-1 Start Date*: 2017-03-03
    Sponsor Name:Isifer AB
    Full Title: A randomized, double blind, controlled, parallel group, multi-centre phase II clinical study of lidocaine pertubation as a treatment for couples with unexplained infertility
    Medical condition: Unexplained infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003401-87 Sponsor Protocol Number: SND103285 Start Date*: 2006-02-15
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed) FR (Completed) EE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001877-97 Sponsor Protocol Number: LPRI-424/302 Start Date*: 2020-02-19
    Sponsor Name:Chemo Research S.L.
    Full Title: A multicentre, double-blind, double-dummy, randomised trial on the contraceptive efficacy, tolerability and safety of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during nine cycles in com...
    Medical condition: Oral contraception for females aged 18-45
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    21.1 10042613 - Surgical and medical procedures 10030970 Oral contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed) CZ (Completed) SK (Completed) HU (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004844-43 Sponsor Protocol Number: MK-0517-045 Start Date*: 2019-10-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CIN...
    Medical condition: Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) PL (Completed) HU (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019290-15 Sponsor Protocol Number: IMCgp100/01 Start Date*: 2010-08-13
    Sponsor Name:Immunocore Ltd
    Full Title: A Phase I/II, Open label, Dose Finding Study to Assess the Safety, Tolerability and Efficacy of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein in Patients With Advanced Maligna...
    Medical condition: Advanced Malignant Melanoma in patients with Stage IV or unresectable Stage III disease for whom no standard effective therapy exists.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005033-16 Sponsor Protocol Number: ASTX295-01 Start Date*: 2022-12-07
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors
    Medical condition: Subjects with Wild-Type TP53 Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003284-35 Sponsor Protocol Number: ABX464-102 Start Date*: 2017-12-19
    Sponsor Name:ABIVAX
    Full Title: A follow-up Phase IIa study to evaluate the long-term safety and efficacy profile of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.
    Medical condition: Moderate to severe Ulcerative Colitis.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) PL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002207-34 Sponsor Protocol Number: 63569 Start Date*: 2018-08-29
    Sponsor Name:Anja Bisgaard Pinborg
    Full Title: Preparing and timing of the endometrium in modified natural cycle frozen-thawed embryo transfers (mNC-FET) - a randomized controlled multicenter trial
    Medical condition: Infertility
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004398-30 Sponsor Protocol Number: ABX464-108 Start Date*: 2021-11-29
    Sponsor Name:Abivax
    Full Title: A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis
    Medical condition: Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) SI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003016-45 Sponsor Protocol Number: APCP-112 Start Date*: 2013-09-11
    Sponsor Name:Araim Pharmaceuticals
    Full Title: A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis
    Medical condition: small fiber neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001307-35 Sponsor Protocol Number: FE999906 CS004 Start Date*: 2005-12-22
    Sponsor Name:Ferring Arzneimittel GmbH
    Full Title: A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified Menotrophin versus recombinant FSH (Follitropin alfa) administered...
    Medical condition: sub fertility
    Disease: Version SOC Term Classification Code Term Level
    7.1 10042391 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003858-85 Sponsor Protocol Number: HFIRONT Start Date*: 2020-02-24
    Sponsor Name:Medical University Innsbruck
    Full Title: Randomized double-blind explorative controlled clinical trial analyzing the effects of ferric carboxymaltose in patients with iron deficiency and chronic heart failure
    Medical condition: This is a randomized double-blind explorative controlled clinical Trial that analyses the effects of 1000mg ferric carboxymaltose in patients with chronic heart failure and iron deficiency.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003556-20 Sponsor Protocol Number: 1806-LIS-044-SD Start Date*: 2019-06-17
    Sponsor Name:INSTITUTO VALENCIANO DE INFERTILIDADE - CLÍNICA DE REPRODUÇÃO ASSISTIDA, LDA
    Full Title: How do different ovarian stimulation protocols affect endometrial receptivity during a fresh in vitro fertilization attempt?
    Medical condition: Women with a clinical indication to undergo Assisted Reproductive Technologies for infertility with a predicted normal response to Ovarian Stimulation and planned for a single blastocyst transfer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003219-26 Sponsor Protocol Number: MR-130A-01-TD-2001 Start Date*: 2023-01-10
    Sponsor Name:Mylan Pharmaceuticals, Inc
    Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women
    Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    22.0 10042613 - Surgical and medical procedures 10073728 Hormonal contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004568-72 Sponsor Protocol Number: ASTX029-01 Start Date*: 2021-05-27
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10053571 Melanoma LLT
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022648-19 Sponsor Protocol Number: P05898 Start Date*: 2011-11-16
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: A 26-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed episodes Associated With Bipolar I Disorder
    Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068455 Bipolar I disorder, hypomanic LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002731-14 Sponsor Protocol Number: 16I-Prg05 Start Date*: 2017-02-20
    Sponsor Name:IBSA INSTITUT BIOCHIMIQUE SA
    Full Title: Prospective, randomised, double-blind, placebo controlled, phase III clinical study assessing the efficacy of 25 mg natural progesterone administered subcutaneously in restoring the normal luteal p...
    Medical condition: Women with diagnosis of luteal phase deficiency.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10063291 Progesterone PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036562 Pregnancy in habitual aborter PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003076-37 Sponsor Protocol Number: SB205 Start Date*: 2005-09-02
    Sponsor Name:Sanos Bioscience A/S
    Full Title: GLP-2 and Bone Resorption. A double-blind, randomized, placebo-controlled, dose ranging, safety, tolerability and pharmacokinetic/dynamic efficacy study with multiple subcutaneous injections of GL...
    Medical condition: postmenopausal women with osteopenia (BMD T-score -2.5 < T ≤ -1.0) at one or more of the regions: the lumbar spine, femoral neck or total hip.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:26:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA